We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

By LabMedica International staff writers
Posted on 07 Jun 2016
Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells.

The three-dimensional print electronics developer Nano Dimension (Ness Ziona, Israel) collaborated with Accellta (Haifa, Israel), which has developed proprietary technologies for the production of high quality media, stem cells, progenitors, and differentiated cells for drug discovery, regenerative medicine, and research.

Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

The partners recently announced that they had successfully tested a proof-of-concept three-dimensional bioprinter for stem cells. The ability of the printer to generate stem cells was due in part to Accellta's robust and reproducible suspension-based cell culturing systems that produce billions of high quality stem cells per batch.

Amit Dror, CEO of Nano Dimension, said, "Three-dimensional printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control, and viability as well as cell availability and bio-ink technologies. By combining our high speed, high precision inkjet capabilities with Accellta's stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable three-dimensional printing at high resolution and high volumes."

Dr. Itzchak Angel, CEO of Accellta, said, "Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies. We hope and believe that this will bring the mutual capabilities and know-how of both companies to create three-dimensional bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision three-dimensional bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development."

Related Links:
Nano Dimension
Accellta

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries